Evaluation of the Effectiveness of Additional Risk Minimization Measures for Ixazomib Citrate for Relapsed/Refractory Multiple Myeloma in Japan: A Web-Based Survey Among Pharmacists.

IF 3.1 Q2 PHARMACOLOGY & PHARMACY Pharmaceutical Medicine Pub Date : 2024-09-01 Epub Date: 2024-08-21 DOI:10.1007/s40290-024-00535-w

Yoshiko Maeda, Akihito Abe, Seigo Seki, Nobuhiro Narii, Yasuhiro Katsura, Yukiko Muramatsu, Motonobu Sakaguchi

{"title":"Evaluation of the Effectiveness of Additional Risk Minimization Measures for Ixazomib Citrate for Relapsed/Refractory Multiple Myeloma in Japan: A Web-Based Survey Among Pharmacists.","authors":"Yoshiko Maeda, Akihito Abe, Seigo Seki, Nobuhiro Narii, Yasuhiro Katsura, Yukiko Muramatsu, Motonobu Sakaguchi","doi":"10.1007/s40290-024-00535-w","DOIUrl":null,"url":null,"abstract":"Background: Ixazomib citrate (IXA) in combination with lenalidomide and dexamethasone (IRD therapy) has been approved for the treatment of relapsed or refractory multiple myeloma. In Japan, as these three drugs have different dosing schedules, dosing instructions for patients have been prepared and distributed to patients via healthcare professionals to promote an understanding of the appropriate dosing regimen, as an additional risk minimization measure (aRMM).Objectives: This survey aimed to investigate whether the aRMM material is being utilized for the adequate use of IXA.Methods: A web-based questionnaire survey was conducted among in-hospital pharmacists in Japan who instructed patients on IXA dosing for IRD therapy. The primary endpoint was the proportion of pharmacists who provided patients with the contents of the aRMM material (i.e., how to take IXA). The secondary endpoints were the proportion of pharmacists who had obtained the aRMM material and the proportion of pharmacists who understood the importance of explaining how to take IXA to patients.Results: Of the 330 pharmacists who completed the questionnaire, 93.0% answered that they had explained how to take IXA to patients. Of those who answered that they had explained how to take IXA, 33.2% responded that they had experience in using the aRMM material. In addition, 37.6% of the pharmacists answered that they had obtained the aRMM material. Moreover, 95.8% stated that they knew how to take IXA, and 90.3, 9.1, 0.3, and 0.3% of pharmacists answered that the importance of explaining how to take IXA was \"very important,\" \"probably important,\" \"less important\" and \"not important,\" respectively.Conclusions: How to take IXA was explained to patients by pharmacists and the aRMM material was utilized at the time of the explanation, indicating that the aRMM material contributes to the promotion of the appropriate use of IXA.","PeriodicalId":19778,"journal":{"name":"Pharmaceutical Medicine","volume":" ","pages":"373-380"},"PeriodicalIF":3.1000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11473584/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40290-024-00535-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Ixazomib citrate (IXA) in combination with lenalidomide and dexamethasone (IRD therapy) has been approved for the treatment of relapsed or refractory multiple myeloma. In Japan, as these three drugs have different dosing schedules, dosing instructions for patients have been prepared and distributed to patients via healthcare professionals to promote an understanding of the appropriate dosing regimen, as an additional risk minimization measure (aRMM).

Objectives: This survey aimed to investigate whether the aRMM material is being utilized for the adequate use of IXA.

Methods: A web-based questionnaire survey was conducted among in-hospital pharmacists in Japan who instructed patients on IXA dosing for IRD therapy. The primary endpoint was the proportion of pharmacists who provided patients with the contents of the aRMM material (i.e., how to take IXA). The secondary endpoints were the proportion of pharmacists who had obtained the aRMM material and the proportion of pharmacists who understood the importance of explaining how to take IXA to patients.

Results: Of the 330 pharmacists who completed the questionnaire, 93.0% answered that they had explained how to take IXA to patients. Of those who answered that they had explained how to take IXA, 33.2% responded that they had experience in using the aRMM material. In addition, 37.6% of the pharmacists answered that they had obtained the aRMM material. Moreover, 95.8% stated that they knew how to take IXA, and 90.3, 9.1, 0.3, and 0.3% of pharmacists answered that the importance of explaining how to take IXA was "very important," "probably important," "less important" and "not important," respectively.

Conclusions: How to take IXA was explained to patients by pharmacists and the aRMM material was utilized at the time of the explanation, indicating that the aRMM material contributes to the promotion of the appropriate use of IXA.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

日本对枸橼酸伊沙佐米治疗复发性/难治性多发性骨髓瘤的额外风险最小化措施的效果评估：药剂师网络调查。

背景：枸橼酸伊沙佐米（IXA）联合来那度胺和地塞米松（IRD疗法）已被批准用于治疗复发性或难治性多发性骨髓瘤。在日本，由于这三种药物有不同的给药方案，因此作为一项额外的风险最小化措施（aRMM），我们为患者准备了给药说明书，并通过医护人员分发给患者，以促进他们了解适当的给药方案：本调查旨在了解患者是否利用 aRMM 材料来充分使用 IXA：方法：对日本医院内指导患者使用IXA进行IRD治疗的药剂师进行了网络问卷调查。主要终点是向患者提供 aRMM 材料内容（即如何服用 IXA）的药剂师比例。次要终点是获得 aRMM 材料的药剂师比例，以及了解向患者解释如何服用 IXA 的重要性的药剂师比例：在完成问卷调查的 330 名药剂师中，93.0% 的药剂师回答曾向患者解释过如何服用 IXA。在回答曾向患者解释如何服用 IXA 的药剂师中，有 33.2% 回答他们有使用 aRMM 材料的经验。此外，37.6%的药剂师回答说他们获得了 aRMM 资料。此外，95.8% 的药剂师表示他们知道如何服用 IXA，90.3%、9.1%、0.3% 和 0.3%的药剂师回答解释如何服用 IXA 的重要性分别为 "非常重要"、"可能重要"、"不太重要 "和 "不重要"：结论：药剂师向患者解释了如何服用 IXA，并在解释时使用了 aRMM 资料，这表明 aRMM 资料有助于促进 IXA 的合理使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pharmaceutical Medicine PHARMACOLOGY & PHARMACY-

CiteScore

5.10

自引率

4.00%

发文量

期刊介绍： Pharmaceutical Medicine is a specialist discipline concerned with medical aspects of the discovery, development, evaluation, registration, regulation, monitoring, marketing, distribution and pricing of medicines, drug-device and drug-diagnostic combinations. The Journal disseminates information to support the community of professionals working in these highly inter-related functions. Key areas include translational medicine, clinical trial design, pharmacovigilance, clinical toxicology, drug regulation, clinical pharmacology, biostatistics and pharmacoeconomics. The Journal includes:Overviews of contentious or emerging issues.Comprehensive narrative reviews that provide an authoritative source of information on topical issues.Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by PRISMA statement.Original research articles reporting the results of well-designed studies with a strong link to wider areas of clinical research.Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Pharmaceutical Medicine may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.